Chiara Mercinelli (@cmercinelli) 's Twitter Profile
Chiara Mercinelli

@cmercinelli

Born in Taranto - Fellow Research GU-Oncology Resident at IRCCS San Raffaele Hospital

ID: 871449401268555776

calendar_today04-06-2017 19:31:42

112 Tweet

235 Followers

250 Following

CancerNetwork® (@cancernetwrk) 's Twitter Profile Photo

“[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease," said Chiara Mercinelli, MD. #AUA24 | Amer. Urol. Assn. Chiara Mercinelli cancernetwork.com/view/nivolumab…

Andrea Necchi (@andreanecchi) 's Twitter Profile Photo

Profoundly honored to serve as new Associate Editor ⁦Journal of Clinical Oncology⁩ continuing the path of Mike Carducci | a special thank to the EiC ⁦Jonathan Friedberg⁩ and the exceptional editorial staff ⁦ASCO⁩ ⁦Università Vita-Salute San Raffaele⁩ ⁦⁦Ospedale San Raffaele⁩ ascopubs.org/jco/about/edit…

Andrea Necchi (@andreanecchi) 's Twitter Profile Photo

IDO1 inhibition was ineffective in UC. Pembrolizumab+epacadostat/placebo for cis-ineligible mUC: ECHO-307/KEYNOTE-672 study | BMC Cancer | also negatively tested in neoadjuvant setting #Optimus ⁦Petros Grivas⁩ ⁦Michiel van der Heijden⁩ #Ronald deWit bmccancer.biomedcentral.com/articles/10.11…

Andrea Necchi (@andreanecchi) 's Twitter Profile Photo

Out in Journal of Clinical Oncology our next piece of the neoadjuvant puzzle in muscle-invasive #bladdercancer. Taxanes could be another good choice of backbone chemo to combine with IO, overcoming the known limits of platinum. #NureCombo provided Nivo/ABX x4 > RC > adj Nivo x13. N=31. 22 pts

Andrea Necchi (@andreanecchi) 's Twitter Profile Photo

Finally, educational and growing career path of neoadjuvant platform continued. Commitment of pts and families, first author resident Chiara Mercinelli And the outstanding team made this idea possible Valentina Tateo Antonio Cigliola Brigida Maiorano miriam borella Gaia Latini

Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

The NURE-Combo trial shows promising results with a combination of nivolumab & nab-paclitaxel as neoadjuvant therapy, achieving 32.3% pathologic complete response & 70.9% major pathologic response rates. #oncology #cancer #immunotherapy Andrea Necchi OncoAlert Alberto Briganti

The NURE-Combo trial shows promising results with a combination of nivolumab & nab-paclitaxel as neoadjuvant therapy, achieving 32.3% pathologic complete response & 70.9% major pathologic response rates. 
#oncology #cancer #immunotherapy <a href="/AndreaNecchi/">Andrea Necchi</a> <a href="/OncoAlert/">OncoAlert</a> <a href="/Albert0Briganti/">Alberto Briganti</a>
Giovanni Pastorino (@gio_pasto_real) 's Twitter Profile Photo

Finally out!! Neoadjuvant Nivo + ABX with 35.7% pCR and nearly 70% pMR in MIBC regardless of platinum eligibility. Lower PB fraction of PMN-MDSCs and intermediate monocyte in pCR but at baseline only. CD11b+CD33hi monos increase from baseline to C2D1. Next step: SG +/- Pembro

Finally out!! Neoadjuvant Nivo + ABX with 35.7% pCR and nearly 70% pMR in MIBC regardless of platinum eligibility. Lower PB fraction of PMN-MDSCs and intermediate monocyte in pCR but at baseline only. CD11b+CD33hi monos increase from baseline to C2D1. Next step: SG +/- Pembro
UroToday.com (@urotoday) 's Twitter Profile Photo

What’s on the horizon for metastatic #ProstateCancer patients? Looking forward to this informative session, Saturday at #ESMO24. Presentations from Misha Beltran, Neeraj Agarwal, MD, FASCO, Wilbert Zwart, and Juliet Carmichael, and more! Written coverage to follow on UroToday! ESMO - Eur. Oncology

What’s on the horizon for metastatic #ProstateCancer patients? Looking forward to this informative session, Saturday at #ESMO24. Presentations from <a href="/mishabeltran/">Misha Beltran</a>, <a href="/neerajaiims/">Neeraj Agarwal, MD, FASCO</a>, Wilbert Zwart, and Juliet Carmichael, and more! Written coverage to follow on UroToday! <a href="/myESMO/">ESMO - Eur. Oncology</a>